TABLE 2.
Combined totals | Office (excluding telemedicine) | Blended telemedicine | Telemedicine (excluding office) | Office versus blended‐telemedicine | Office versus telemedicine | |
---|---|---|---|---|---|---|
HEDIS specified ‐ follow up plan within the study timeframe | ||||||
Follow up plan | 43,003 | 27,109 | 15,771 | 123 | Difference 12.65% 95% CI 12.2886% to 13.0137%Chi‐squared 6198.379 p < 0.0001 | Difference 4.29% 95% CI 2.8374%–5.5364% chi‐squared 26.623 p < 0.0001 |
BMI outside normal range | 287,378 | 222,333 | 63,489 | 1556 | ||
Quality performance | 14.96% | 12.19% | 24.84% | 7.90% | ||
HEDIS modified ‐ follow up plan within 3 months of provider encounter | ||||||
Follow up plan | 25,948 | 14,648 | 11,272 | 28 | Difference: 11.16% 95% CI: 10.8470%–11.4762% chi‐squared: 7458.725 p < 0.0001 | Difference: 4.79% 95% CI3.9943%–5.3514% chi‐squared: 57.865 p < 0.0001 |
BMI outside normal range | 287,378 | 222,333 | 63,489 | 1556 | ||
Quality performance | 9.03% | 6.59% | 17.75% | 1.80% |
Note: Data represents patients seen from 4/1/20 ‐ 9/30/21 with BMI <18.5 or >25 meeting HEDIS specified criteria for abnormal BMI prevention. Comparisons reported as absolute percent differences in quality performance between exposure groups. Two comparisons: (1) office only versus blended telemedicine and (2) office only versus telemedicine only. Significant p‐values indicate true differences between quality performance in exposure groups favoring blended‐telemedicine overall.